XFOR Share Price Performance
US$3.53
-14.23 (-80.13%)
59.4% undervalued intrinsic discount
US$8.70
Fair Value
Price US$3.53
AnalystConsensusTarget US$8.70
AnalystLowTarget US$7.00
AnalystHighTarget US$120.00
Fair ValueUS$8.70
Share Pricen/a
X4 Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
XFOR Community Narratives
AN
Fair Value US$8.7 59.4% undervalued intrinsic discount
US Launch And EMA Approval Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$3.5 0.9% overvalued intrinsic discount
Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$69.81 94.9% undervalued intrinsic discount
Rising Rare Disease Awareness And Precision Medicine Will Expand Access
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US Launch And EMA Approval Will Expand Global Reach
Key Takeaways The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence. Successful trials and restructuring efforts anticipate improved profitability and financial sustainability while targeting broader patient populations.Read more
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$8.7
59.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
44.05% p.a.
Profit Margin
14.17%
Future PE
10.37x
Share price in 2028
US$5.74
Rising Rare Disease Awareness And Precision Medicine Will Expand Access
Key Takeaways Strong trial results, physician demand, and broad label opportunities could drive faster adoption, revenue growth, and larger market access than currently projected. Strategic cost controls, greater diagnostic momentum, and supportive healthcare trends position X4 for improved profitability, pricing power, and long-term value creation.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$69.81
94.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
127.01% p.a.
Profit Margin
24.71%
Future PE
25.34x
Share price in 2028
US$95.8
Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential
Key Takeaways Reliance on a single drug and competitive pressures from new therapies create significant risks to X4's future growth, profitability, and market share. Ongoing financial losses, regulatory challenges, and capital constraints threaten shareholder value and may delay the company's expansion into new markets.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$3.5
0.9% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-7.8% p.a.
Profit Margin
16.25%
Future PE
28.71x
Share price in 2028
US$4.78
Snowflake Analysis
X4 Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.09
- 83.24%
- -279.86%
- 1,909.9%
About XFOR
- Founded
- n/a
- Employees
- 143
- CEO
- WebsiteView website
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
